Business Standard

Thursday, December 26, 2024 | 07:46 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

India begins human trials of Coviaxin, hoping for Covid-19 vaccine success

Private and state-owned hospitals will test the potential vaccine on volunteers, aged between 18 and 55

Human trials of Coviaxin begin across India as the nation awaits vaccine
Premium

Phase I of the vaccine trial will be done on healthy people, aged between 18 and 55 years, having no co-morbid conditions

BS Web Team New Delhi
Human trials for Covaxin, one of the first potential vaccines developed in India in the fight against Covid-19, is underway in 12 centres across the country.

Covaxin is derived from a strain of the SARS-CoV-2, the virus that causes Covid-19, and it was isolated at the Pune-based National Institute of Virology (NIV). The Indian Council of Medical Research (ICMR) and Bharat Biotech are jointly working for the preclinical as well as clinical development of this vaccine. It has already received approval for phase-I and phase- II human trials by the Drug Controller General of India (DGCI).

The ICMR had identified

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in